Microviable Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Microviable Therapeutics is a private, preclinical-stage biotech focused on harnessing the microbiome to develop live biotherapeutic products (LBPs). The company's core assets are three biological drugs nearing clinical development, targeting oncology and infectious diseases with antibiotic resistance. Beyond its internal pipeline, Microviable offers a range of services including custom biotherapeutic development, microbiota analysis, and markets GutAlive®, an anaerobic microbiome collection kit designed for clinical and research applications. The company appears to be pre-revenue, building value through its platform and pipeline.

OncologyInfectious Diseases

Technology Platform

PharmaBiota® - A proprietary drug discovery and development platform for isolating and developing live biotherapeutic products (LBPs) from the human microbiota, with a focus on maintaining anaerobic bacterial viability. Supported by the GutAlive® anaerobic sample collection kit.

Opportunities

The growing validation of the microbiome's role in oncology and the global crisis of antibiotic resistance create large, unmet medical needs and substantial market opportunities for effective live biotherapeutics.

The company's GutAlive® kit and service offerings provide a potential early revenue stream and a tool to establish partnerships with larger pharmaceutical companies seeking microbiome expertise.

Risk Factors

The company faces significant scientific risk in translating complex microbiome science into safe and effective drugs, and regulatory pathways for live biotherapeutics are still evolving.

As a small, private company, it also carries execution and financing risks in advancing multiple programs to and through clinical trials in a competitive landscape.

Competitive Landscape

Microviable operates in the competitive microbiome therapeutics space, facing rivals like Seres Therapeutics, Vedanta Biosciences, and many other private companies developing LBPs for oncology and infection. Its GutAlive® kit competes with other microbiome sampling products, but its focus on large-volume, anaerobic stabilization at room temperature is a key differentiator.

More companies in Microbiome Therapeutics →More companies in Spain →